Previous 10 | Next 10 |
Organon (NYSE: OGN) (“Organon”), a global healthcare company with a focus on women’s health, announced today that it, together with Organon Foreign Debt Co-Issuer B.V., a direct wholly-owned subsidiary of Organon, as co-issuer (the “Co-Issuer” and, together with...
2024-05-07 12:43:50 ET Summary OGN has underperformed its healthcare peers and the benchmark over the past year, but this could change going forward. The company's dominant women's health product- Nexplanon is looking at double-digit growth in sales this year, even as market loss ...
2024-05-07 08:21:25 ET More on Organon Organon Stock Is Still Worth A Look Organon Q4 And Full Year 2023 Earnings Review - Positive Updates At Last Read the full article on Seeking Alpha For further details see: Organon plans to offer $1B in senior notes
Organon (NYSE: OGN) (“Organon”), a global healthcare company with a focus on women’s health, announced today that it, together with Organon Foreign Debt Co-Issuer B.V., a direct wholly-owned subsidiary of Organon, as co-issuer (the “Co-Issuer” and, together with...
2024-05-02 11:53:39 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Organon (NYSE: OGN ) just reported results for the first quarter of 2024. Organon reported earnings per share of $1.22. This was above the analyst estimate for EPS of 93 c...
2024-05-02 11:09:10 ET Organon & Co. (OGN) Q1 2024 Earnings Conference Call May 2, 2024 8:30 AM ET Company Participants Jennifer Halchak - Vice President, Investor Relations Kevin Ali - Chief Executive Officer Matt Walsh - Chief Financial Officer Confer...
2024-05-02 08:11:46 ET More on Organon Organon Stock Is Still Worth A Look Organon Q4 And Full Year 2023 Earnings Review - Positive Updates At Last Organon & Co. (OGN) Q4 2023 Earnings Call Transcript Organon Non-GAAP EPS of $1.22 beats by $0.29, revenue ...
2024-05-02 07:32:09 ET More on Organon Organon Stock Is Still Worth A Look Organon Q4 And Full Year 2023 Earnings Review - Positive Updates At Last Organon & Co. (OGN) Q4 2023 Earnings Call Transcript Organon Q1 2024 Earnings Preview AbbVie keeps ...
First quarter 2024 revenue of $1,622 million, up 5% on an as-reported basis and 7% at constant currency First quarter 2024 diluted earnings per share of $0.78 and non-GAAP Adjusted diluted earnings per share of $1.22; both reported and non-GAAP Adjusted diluted earnings per share include $15 ...
Resideo Technologies Inc. (REZI) is expected to report $0.33 for Q1 2024 Schneider National Inc. (SNDR) is expected to report $0.13 for Q1 2024 Murphy Oil Corporation (MUR) is expected to report $0.82 for Q1 2024 Astronics Corp. - Class B (ATROB) is expected to report for Q1 2024 ...
News, Short Squeeze, Breakout and More Instantly...
2024-06-08 06:50:00 ET Not all dividend stocks are equal. Some are safer than others. Some have much higher dividend yields than others. When a stock offers both advantages, it's usually a keeper. Three Motley Fool contributors have found stocks with mouthwatering dividends that you...
Shanghai Henlius Biotech, Inc. (2696.HK) and Organon (NYSE: OGN) today announced that the European Medicines Agency (EMA) has validated the marketing authorization applications (MAAs) for HLX14, an investigational Prolia ® and Xgeva ® (denosumab) biosimilar. Denosumab has been a...
2024-05-23 02:50:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...